People

David Perlman
David C. Perlman, MD
CDUHR - Director, Infectious Disease Epidemiology and Social-behavioral Theory Core
Mount Sinai Health System - Professor of Medicine, Icahn School of Medicine
Mount Sinai Health System - Chief, Infectious Diseases, Mount Sinai Beth Israel
Email: david.perlman@mountsinai.org
Education
MD, Medicine, Albert Einstein College of Medicine
BA. Biochemistry & Anthropology, Dartmouth College
Research Interests
HIV, HCV, IDUs, Diagnosis and treatment
BIO
David Perlman has over 20 years’ experience in HIV, HCV, TB and STIs and remains active as a clinician in these areas. He has served as principal investigator on multi-center trials within NIAID’s AIDS Clinical Trials group, and on R01 grants from NIDA. He has served on NIH study sections, CDC consensus panels, and committees within the ACTG, the NYS DOH AIDS Institute, and the NYC DOMH. Dr. Perlman’s earlier work focused on studies of the epidemiology of tuberculosis among drug users, and on health care delivery models and behavioral and structural interventions to facilitate adherence to the TB and HIV/TB care continuum. Dr. Perlman’s recent work has focused on studies of barriers and facilitators of HIV and HCV testing and care among racial and ethnic minorities, high risk heterosexuals, and people who use drugs, and more broadly on studies of strategies to improve HIV and HIV/HCV care continua and prevention programming for these populations.
Projects
Principal Investigator, Hepatitis Care Coordination in Methadone Treatment. Completed
Publications

Recent

Kapadia SN, Jordan AE, Eckhardt BJ, Perlman DC (2023).
The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination
Clinical Infectious Diseases [Epub 2023 Aug 27]. doi: 10.1093/cid/ciad503.

Friedman SR, Perlman DC, Paraskevis D, Feldman J (2023).
Sociopolitical diagnostic tools to understand national and local response capabilities and vulnerabilities to epidemics and guide research into how to improve the global response to pathogens
Pathogens, 12 (8), 1023. doi: 10.3390/pathogens12081023. PMCID: PMC10457759.

Corcorran MA, Austin EJ, Behrends CN, Briggs ES, Frost MC, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN (2023).
Syringe service program perspectives on barriers, readiness, and programmatic needs to support rollout of the COVID-19 vaccine
Journal of Addiction Medicine, 17 (1), e36-e41. doi: 10.1097/ADM.0000000000001036. PMCID: PMC9892351.

Des Jarlais DC, Behrends CN, Corcorran MA, Glick SN, Perlman DC, Kapadia SN, Lu X, Feelemyer J, LaKosky P, Prohaska SM, Schackman BR (2022).
Availability of and obstacles to providing COVID-19 vaccinations at syringe services programs in the United States, 2021
Public Health Reports, 137 (6), 1066-1069. doi: 10.1177/00333549221120241. PMCID: PMC9574299.

Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN (2022).
Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives Copy
International Journal of Drug Policy, 109, 103825. doi: 10.1016/j.drugpo.2022.103825. PMCID: PMC9364718.

Dr. Perlman's MyBibliography Profile